Mirada Medical Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Mirada Medical Limited - overview
Established
2000
Location
Oxford, -, UK
Primary Industry
Software
About
Mirada Medical Limited develops advanced imaging software designed to enhance cancer treatment precision. Their innovative technology improves accessibility and efficiency in diagnostic imaging workflows for healthcare providers. Mirada Medical Limited, founded in 2000, is based in Oxford, UK. The company specializes in advanced imaging solutions for cancer treatment.
It has successfully completed a total of 4 funding deals, with the most recent being a Growth round in June 2022, which raised USD 20. 00 mn from Apposite Capital. The total amount raised to date is also USD 20. 00 mn.
The CEO is Jon DeVries, and the company was founded by Hugh Bettesworth. Mirada Medical specializes in advanced imaging software that enhances the precision and personalization of cancer treatment. Their core products include Mirada XD™, a diagnostic imaging platform, and Simplicit90Y™, designed for interventional radiology and dosimetry. These solutions utilize AI-assisted workflows to streamline processes, particularly in PET/CT reporting, improving patient outcomes by making cancer care more accessible.
Their client base includes hospitals and cancer centers primarily in the UK and the US, focusing on supporting clinicians in radiation oncology and diagnostic imaging. In the most recent year of 2023, Mirada Medical reported a revenue of USD 4,783,413. 20, alongside an EBITDA of USD -4,759,906. 60.
The company’s revenue model is based on B2B transactions, primarily through software subscriptions and partnerships with healthcare institutions. Clients typically engage through structured agreements that involve licensing fees for products like Mirada XD™ and Simplicit90Y™, including setup costs and recurring fees for support and updates. Mirada Medical plans to utilize the USD 20. 00 mn raised in their recent Growth funding round to expand their product offerings and enhance solutions for physicians.
As part of their strategy, the company aims to introduce new products and enhance existing offerings, focusing on specific markets and regions for expansion. The funding will be directed towards achieving these objectives and delivering transformative solutions to improve cancer treatment outcomes.
Current Investors
Albion Capital, Apposite Capital
Primary Industry
Software
Sub Industries
Healthcare IT, Oncology/Cancer Treatment, Analytics & Performance Software, Medical Software
Website
www.mirada-medical.com
Verticals
HealthTech
Company Stage
Growth Stage/Expansion
Total Amount Raised
Subscriber access only
Mirada Medical Limited - timeline of key events
Mirada Medical Limited - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.